Advanced Biomedical Research
Evaluation of miR-21 Inhibition and its Impact on Cancer Susceptibility Candidate 2 Long Noncoding RNA in Colorectal Cancer Cell Line
Document Type : Original Article
Authors
- Miganoosh Simonian 1
- Mohammadreza Sharifi 1
- Reza Nedaeinia 2
- Meysam Mosallaie 1
- Sharifeh Khosravi 1
- Amir Avan 3
- Majid Ghayour-Mobarhan 4
- Hadi Bagheri 1
- Rasoul Salehi 5
1 Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Molecular Medicine Group, Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences; Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences; Gerfa Namayesh Azmayesh (GENAZMA) Science and Research Institute, Isfahan, Iran
Abstract
Background: Both microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) have been shown to have a critical role in the regulation of cellular processes such as cell growth and apoptosis, as well as cancer progression and metastasis. lncRNAs are aberrantly expressed in many diseases including cancer. Although it is well known that miRNAs can target a large number of protein-coding genes, little is known whether miRNAs can also target lncRNAs. In the present study, we determine whether miR-21 can regulate lncRNA cancer susceptibility candidate 2 (CASC2) in colorectal cancer. Materials and Methods: LS174T cells were transfected with locked nucleic acid (LNA)-anti-miR-21 and scrambled LNA for 24, 48 and 72 h. The expression of miR-21 and lncCASC2 was evaluated by quantitative reverse transcriptase polymerase chain reaction. Results: However, contrary to what we expected and reported by others, lncCASC2 quantity was significantly reduced in LNA treated LS174T cells compared to the scrambled treated and normal untreated cells (P < 0.05). Conclusion: The interaction of miRNA and lncRNA are not as simple as suggested by other reports. Moreover, it could be complex molecular mechanisms underlying the communication of various noncoding RNA elements.
Keywords
| 1. |
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.  [PUBMED] |
| 2. |
O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg 2003;69:866-72. |
| 3. |
Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 2009;18:1695-8. [PUBMED] |
| 4. |
Sun BO, Li W, Liu N. Curative effect of the recent photofrin photodynamic adjuvant treatment on young patients with advanced colorectal cancer. Oncol Lett 2016;11:2071-4. [PUBMED] |
| 5. |
Slaby O. Non-coding RNAs as biomarkers for colorectal cancer screening and early detection. Non-coding RNAs in Colorectal Cancer: Springer; 2016. p. 153-70. |
| 6. | |
| 7. |
Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011;10:38. [PUBMED] |
| 8. |
Gibb EA, Vucic EA, Enfield KS, Stewart GL, Lonergan KM, Kennett JY, et al. Human cancer long non-coding RNA transcriptomes. PLoS One 2011;6:e25915. [PUBMED] |
| 9. |
Mohammad F, Pandey GK, Mondal T, Enroth S, Redrup L, Gyllensten U, et al. Long noncoding RNA-mediated maintenance of DNA methylation and transcriptional gene silencing. Development 2012;139:2792-803. [PUBMED] |
| 10. |
Ng SY, Johnson R, Stanton LW. Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. EMBO J 2012;31:522-33. [PUBMED] |
| 11. |
Piao HL, Ma L. Non-coding RNAs as regulators of mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2012;17:33-42. [PUBMED] |
| 12. |
Silva JM, Boczek NJ, Berres MW, Ma X, Smith DI. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol 2011;8:496-505. [PUBMED] |
| 13. |
Sun M, Xia R, Jin F, Xu T, Liu Z, De W, et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 2014;35:1065-73. [PUBMED] |
| 14. |
Li H, Yu B, Li J, Su L, Yan M, Zhu Z, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 2014;5:2318-29. [PUBMED] |
| 15. |
Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett 2013;333:213-21. [PUBMED] |
| 16. |
Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst 2012;8:2289-94. [PUBMED] |
| 17. |
Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013;8:e65309. [PUBMED] |
| 18. |
Kong PR. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015;6:22513-5. |
| 19. |
Wu ZH, Wang XL, Tang HM, Jiang T, Chen J, Lu S, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep 2014;32:395-402. [PUBMED] |
| 20. |
Han L, Zhang K, Shi Z, Zhang J, Zhu J, Zhu S, et al. LncRNA profile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis. Int J Oncol 2012;40:2004-12. [PUBMED] |
| 21. |
Kornienko AE, Guenzl PM, Barlow DP, Pauler FM. Gene regulation by the act of long non-coding RNA transcription. BMC Biol 2013;11:59. [PUBMED] |
| 22. |
Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. Along noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011;147:358-69. [PUBMED] |
| 23. |
Baldinu P, Cossu A, Manca A, Satta MP, Sini MC, Rozzo C, et al. Identification of a novel candidate gene, CASC2, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer. Hum Mutat 2004;23:318-26. [PUBMED] |
| 24. |
Behm-Ansmant I, Rehwinkel J, Doerks T, Stark A, Bork P, Izaurralde E. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev 2006;20:1885-98. [PUBMED] |
| 25. |
Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005;122:553-63. [PUBMED] |
| 26. |
Cheng LC, Tavazoie M, Doetsch F. Stem cells: From epigenetics to microRNAs. Neuron 2005;46:363-7. [PUBMED] |
| 27. |
Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-6. [PUBMED] |
| 28. |
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. AmicroRNA polycistron as a potential human oncogene. Nature 2005;435:828-33. [PUBMED] |
| 29. |
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36. [PUBMED] |
| 30. |
Li S, Liang Z, Xu L, Zou F. MicroRNA-21: A ubiquitously expressed pro-survival factor in cancer and other diseases. Mol Cell Biochem 2012;360:147-58. [PUBMED] |
| 31. |
Schetter AJ, Harris CC. Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol 2011;38:734-42. [PUBMED] |
| 32. |
Yamamichi N, Shimomura R, Inada K, Sakurai K, Haraguchi T, Ozaki Y, et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res 2009;15:4009-16. [PUBMED] |
| 33. |
Wang P, Liu YH, Yao YL, Li Z, Li ZQ, Ma J, et al. Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. Cell Signal 2015;27:275-82. [PUBMED] |
| 34. |
Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20. [PUBMED] |
| 35. |
Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006;95:921-7. [PUBMED] |
| 36. |
Yang G, Lu X, Yuan L. LncRNA: A link between RNA and cancer. Biochim Biophys Acta 2014;1839:1097-109. [PUBMED] |
| 37. |
Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007;26:2799-803. [PUBMED] |
| 38. |
Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008;68:8164-72. [PUBMED] |
| 39. |
Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, Iwamoto K, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009;114:3265-75. [PUBMED] |
| 40. |
Jeggari A, Marks DS, Larsson E. miRcode: A map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics 2012;28:2062-3. [PUBMED] |
| 41. |
He X, Liu Z, Su J, Yang J, Yin D, Han L, et al. Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer. Tumour Biol 2016;37:9503-10. [PUBMED] |
| 42. |
Cao Y, Xu R, Xu X, Zhou Y, Cui L, He X. Downregulation of lncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells. Mol Med Rep. 2016;14:1019-25.
|
)